BR112022008862A2 - Inibidor de srebp que compreende um anel central de tiofeno - Google Patents
Inibidor de srebp que compreende um anel central de tiofenoInfo
- Publication number
- BR112022008862A2 BR112022008862A2 BR112022008862A BR112022008862A BR112022008862A2 BR 112022008862 A2 BR112022008862 A2 BR 112022008862A2 BR 112022008862 A BR112022008862 A BR 112022008862A BR 112022008862 A BR112022008862 A BR 112022008862A BR 112022008862 A2 BR112022008862 A2 BR 112022008862A2
- Authority
- BR
- Brazil
- Prior art keywords
- srebp
- compound
- thiophene ring
- pharmaceutically acceptable
- methods
- Prior art date
Links
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 title abstract 6
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 title abstract 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- -1 (4 hydroxypiperidin 1 yl) methanone compound Chemical class 0.000 abstract 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091006088 activator proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INIBIDOR DE SREBP QUE COMPREENDE UM ANEL CENTRAL DE TIOFENO. A presente invenção refere-se a composto de (3 cloro 4 (4 (2 (2 hidroxipropan 2 il)piridin 4 il)tiofen 2 il)fenil)(4 hidroxipiperidin 1 il)metanona (Composto 1) e sais, solvatos, tautômeros, isótopos ou isômeros farmaceuticamente aceitáveis dos mesmos. A invenção ainda se refere a métodos para inibir um componente da via da proteína de ligação ao elemento regulador de esterol (SREBP), tal como uma proteína ativadora de clivagem de SREBP ou SREBP (SCAP), usando o Composto 1, ou um sal, solvato, tautômero, isótopo ou isômero farmaceuticamente aceitável do mesmo. Além disso, são fornecidos métodos de tratamento de um distúrbio em um indivíduo em necessidade do mesmo, tais como doença hepática, esteato hepatite não alcoólica, resistência à insulina ou câncer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935028P | 2019-11-13 | 2019-11-13 | |
| US202062966356P | 2020-01-27 | 2020-01-27 | |
| US202063056408P | 2020-07-24 | 2020-07-24 | |
| PCT/US2020/060276 WO2021097122A1 (en) | 2019-11-13 | 2020-11-12 | Srebp inhibitor comprising a thiophene central ring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008862A2 true BR112022008862A2 (pt) | 2022-08-23 |
Family
ID=75912882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008862A BR112022008862A2 (pt) | 2019-11-13 | 2020-11-12 | Inibidor de srebp que compreende um anel central de tiofeno |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220356170A1 (pt) |
| EP (1) | EP4058014A4 (pt) |
| JP (1) | JP2023502604A (pt) |
| KR (1) | KR20220128335A (pt) |
| CN (1) | CN114945365A (pt) |
| AU (1) | AU2020381462A1 (pt) |
| BR (1) | BR112022008862A2 (pt) |
| CA (1) | CA3157442A1 (pt) |
| MX (1) | MX2022005826A (pt) |
| TW (1) | TW202128678A (pt) |
| WO (1) | WO2021097122A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200128531A (ko) | 2018-01-29 | 2020-11-13 | 카풀루스 테라퓨틱스, 엘엘씨 | 6원 중심 고리를 포함하는 srebp 억제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052813A1 (en) * | 2011-10-06 | 2013-04-11 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| JP2016534124A (ja) * | 2013-08-29 | 2016-11-04 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 代謝並びに体重関連疾患の処置のための組成物および方法 |
| JP2018507235A (ja) * | 2015-03-04 | 2018-03-15 | メディベイション テクノロジーズ エルエルシー | ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤 |
| JP2018507234A (ja) * | 2015-03-04 | 2018-03-15 | メディベイション テクノロジーズ エルエルシー | 肝臓線維症、コレステロールの上昇およびインスリン抵抗性を処置する際における使用のためのｓｒｅｂｐ遮断薬 |
| EP3917513A4 (en) * | 2019-01-28 | 2022-11-09 | Capulus Therapeutics, LLC | SREBP INHIBITORS WITH A THIOPHENE CENTER RING |
| MX2021009426A (es) * | 2019-02-11 | 2021-09-10 | Merck Patent Gmbh | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. |
| TW202128676A (zh) * | 2019-11-13 | 2021-08-01 | 美商卡普勒斯療法有限責任公司 | 具有環醯胺的噻吩化合物及其用途 |
-
2020
- 2020-11-12 WO PCT/US2020/060276 patent/WO2021097122A1/en unknown
- 2020-11-12 EP EP20887697.9A patent/EP4058014A4/en active Pending
- 2020-11-12 JP JP2022527681A patent/JP2023502604A/ja active Pending
- 2020-11-12 MX MX2022005826A patent/MX2022005826A/es unknown
- 2020-11-12 CA CA3157442A patent/CA3157442A1/en active Pending
- 2020-11-12 CN CN202080092448.4A patent/CN114945365A/zh active Pending
- 2020-11-12 AU AU2020381462A patent/AU2020381462A1/en active Pending
- 2020-11-12 TW TW109139474A patent/TW202128678A/zh unknown
- 2020-11-12 BR BR112022008862A patent/BR112022008862A2/pt not_active Application Discontinuation
- 2020-11-12 KR KR1020227019782A patent/KR20220128335A/ko unknown
-
2022
- 2022-05-12 US US17/743,235 patent/US20220356170A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021097122A1 (en) | 2021-05-20 |
| TW202128678A (zh) | 2021-08-01 |
| US20220356170A1 (en) | 2022-11-10 |
| AU2020381462A1 (en) | 2022-06-02 |
| CN114945365A (zh) | 2022-08-26 |
| EP4058014A4 (en) | 2023-12-13 |
| MX2022005826A (es) | 2022-08-16 |
| JP2023502604A (ja) | 2023-01-25 |
| EP4058014A1 (en) | 2022-09-21 |
| CA3157442A1 (en) | 2021-05-20 |
| KR20220128335A (ko) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0518315A2 (pt) | compostos de tiazol que modulam a atividade da proteÍna hsp90, mÉtodos de inibiÇço, tratamento e induÇço associados e composiÇço farmacÊutica | |
| NO20090469L (no) | Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav | |
| BR112016002268A2 (pt) | inibidores do receptor x farnesoide e usos na medicina | |
| PL415078A1 (pl) | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków | |
| MX2019007234A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos. | |
| BR112017017529A2 (pt) | derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo | |
| MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| SG11201900298RA (en) | Heterocyclic compound used as fgfr inhibitor | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| BR112021019465A2 (pt) | Compostos que têm como alvo prmt5 | |
| UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
| PH12019502425A1 (en) | Crystalline forms of a jak inhibitor compound | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| PH12019550083A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| BR112022008862A2 (pt) | Inibidor de srebp que compreende um anel central de tiofeno | |
| BR112017023164A2 (pt) | composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo | |
| MY201291A (en) | Aminothiazole compounds as protein kinase inhibitors | |
| BR112021019817A2 (pt) | Compostos de pirrol | |
| MXPA05008688A (es) | Derivados tetraciclicos de pirazol como inhibidores de la cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
| WO2020159889A9 (en) | Srebp inhibitors comprising a thiophene central ring | |
| AR116877A1 (es) | 3-amino-piridazinas como inhibidores de atx | |
| MX2022016357A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| WO2007081572A3 (en) | Inhibitors of checkpoint kinases | |
| WO2006074281A3 (en) | Inhibitors of checkpoint kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |